HARMONY: European Network of Excellence for Big Data in Hematology
|
|
- Brian Moody
- 6 years ago
- Views:
Transcription
1 European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. HARMONY: European Network of Excellence for Big Data in Hematology Barcelona, 5 de marzo de 2018 Jesús M. Hernández HARMONY Coordinator Institute of Biomedical Research of Salamanca (IBSAL) Funded by
2 What is HARMONY?
3 IMI: Innovative Medicines Initiative Europe s largest public-private partnership in healthcare to speed up development of and patient access to new medicines BD4BO: Big Data for Better Outcomes Initiative within IMI seeking to leverage big data to improve outcomes Initiatives in different disease areas IMI projects addressing BD4BO's key enablers in different therapeutic areas 1.6 B funding for public partners 3.3 B Partnership B in-kind (data, capabilities, FTEs) During first phase ( ), IMI budget of 2 billion, half of which came from the EU's FP7, and half of which came from in kind contributions by EFPIA companies 4 key enablers Design sets of standard outcomes and demonstrate value Increase access to high quality outcomes data Use data to improve value of HC delivery Increase patient engagement through digital solutions HARMONY is a key initiative within IMI Funded by
4 "Big data for better outcomes" Goal: Support the evolution towards outcomes-focused and sustainable healthcare systems, exploiting the opportunities offered by large data sets from variable sources DO-IT COORDINATION AND SUPPORT ACTION (CSA) (Launched) EUROPEAN DISTRIBUTED DATA NETWORK Design sets of standard outcomes and demonstrate value Increase access to high quality outcomes data HARMONY: HEMATOLOGIC MALIGNANCIES ROADMAP: ALZHEIMER'S DISEASE (Launched) BIGDATA@HEART: CARDIOVASCULAR (Launched) PIONEER: PROSTATE CANCER (Consortium formed) HEALTH OUTCOMES IN MULTIMORBID PATIENTS Use data to improve value of HC delivery Increase patient engagement through digital solutions PLANNED PROJECTS Future topic proposals, e.g. respiratory, oncology and ophthalmology Under the "BD4BO" umbrella, HMs is currently the largest program Funded by
5 WP1 Project management (IBSAL, NOVARTIS, CELGENE, HULAFE, SYNAPSE) All Partners Specific questions by disease Involvement of KOLs and collaborative Working Groups Molecular and Clinical Data MM AML ALL CLL NHL MDS Sonneveld San Miguel Boccadoro WP5 Ossenkoppele Huntly Lo Coco WP3 WP4 Gökbuget Dombret Ribera Ghia Pospisilova Bosch Salles Dreyling Montoto Data access (GMV, JANSSEN, BAYER) Data platform (ELN, JANSSEN) Fenaux Kuendgen Santini Child HM Moorman Reinhardt Locatelli Data analytics for therapies valuation (UNIBO, MENARINI, JANSSEN) WP2 Outcomes definition (UULM, BAYER, TAKEDA) WP6 HTA, EMA, patients integration (LeukaNET, CELGENE, JANSSEN) WP7 Dissemination & Communication (EHA, NOVARTIS, TAKEDA) Legal, Ethics & Expert Governance Advisory (MUW, Panel AMGEN, BAYER) WP8 8 Work Packages across 7 diseases Funded by
6 organisations from 11 european countries, including 8 pharmaceutical companies Funded by
7 Ethics Hematologists Pharma Industry Economists Policy makers Regulators Bioinformaticians, data scientists & ICT HTAs Involving every stakeholder group is necessary to meet patients' needs Funded by
8 Data Sharing
9 Data intake and storage Harmonisation Analysis Data Sources Honest Broker Data preparation Data Brokerage CNAF OMOP Our database is ready to work Funded by
10 Source Data Data Preparation Data Brokerage Data Harmonization BigData Storage Data Intake Harmonized Data Storage Data Analysis and Visualization Data Source Trusted Third Party Harmony Platform.. Data Pipeline Funded by
11 Data Privacy And Protection: Legal And Ethical Implications
12 Objectives of the data management process Make the data available in a format that optimally addresses the research questions while respecting the applicable legal and regulatory requirements. De Facto Anonymization Definition Data for which attributing the individual data to the relevant individual concerned requires unreasonable effort in terms of time, cost and manpower. Funded by
13 Privacy and Security HARMONY Platform protection VPN (Virtual Private Network) Firewall with two levels Audit: WHO, WHEN, WHERE, WHAT, HOW Risk analysis Named access Roles' segregation Data governance: nobody has access to the data Physical Layer Applying controls and security to 4 layers Network Layer Host Layer Application / Services Layer The platform is hosted on CNAF Hosting with ISO Funded by
14 Technical anonymisation Data Access Restrictions Organizational security Supression Generalisation Perturbation Policies Processes Contracts Green light for data intake: de-facto anonymization Funded by
15 Research Projects: Standard Operational Procedure
16 START Project proposal Submission HARMONY Coordination Office - Research Project (RP) Submission & Evaluation Admission Scientific Assessment Evaluation Clearance CLARIFICATIONS EXECUTION Coordinator & WP2 Leaders Yes No WP2 HM Pillar KOLs WP6 HTAs, Payers, and Patients, Evaluation WP4&5 Data Analytics WP8 Legal and Ethics Compliance No Yes Yes Yes Yes If RP has scientific merit APPROVAL ASSESMENT WP6 INPUT Report WP4&5 INPUT Report ETHICS Report REVIEW MATERIALS PROVIDED No
17 WP2 Outcomes definition (UULM, BAYER, TAKEDA) Public KOLs EFPIA Disease Contacts HTA, EMA, patients integration (LeukaNET, CELGENE, JANSSEN) WP6 ALL Gökbuget Dombret Ribera Jens Hasskarl, Celgene Marieke Schoonen, AMGEN Zack Pemberton Whiteley Data analytics for therapies valuation (UNIBO, MENARINI, JANSSEN) WP4 WP3 Data access (GMV, JANSSEN, BAYER) Data platform (ELN, JANSSEN) AML CLL NHL MDS MM Ossenkoppele Huntly Lo Coco Ghia Pospisilova Bosch Salles Dreyling Montoto Fenaux Kuendgen Santini Sonneveld San Miguel Boccadoro Christina Loefgren Alberto Vasconcelos, Celgene Rory Goodbody, AbbVie Christina Loefgren, Janssen Sante Cundari, Celgene Christina Pelizon, Abbvie Anne I. Merlat-Guitard, Novartis Sushant Hardikar, Abbvie Christina Loefgren, Janssen Bruno Costa, Celgene Bianca Witting, Abbvie Zack Pemberton Whiteley Nick York TBD Sophie Wintrich Kate Morgan WP5 Child HM Moorman Reinhardt Locatelli TBD Anita Kienesberger 8 Work Packages across 7 diseases Funded by
18 Thank you!
19 Any Questions?
20 This material is developed by the HARMONY Alliance Disclaimer This presentation is of scientific nature and has been produced by the HARMONY Alliance. The HARMONY Alliance makes no warranties or representations of any kind as to the content's accuracy, currency or completeness, neither the Alliance nor any party involved in creating, producing or delivering this document shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this document, or any errors or omissions in the content thereof. This material may not be used for commercial purposes. Remixing is not permitted except for private use. Acknowledgement This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under HARMONY Grant Agreement n This Joint Undertaking receives support from the European Union s Horizon 2020 Research and Innovation Programme and EFPIA.
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA?
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA? Jesús M. Hernández Rivas Instituto de Investigación Biomédica de Salamanca. Universidad de Salamanca. Servicio de Hematología. Hospital Universitario de Salamanca.
EU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme. Stephan Korte, Kim Cryns
Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme Stephan Korte, Kim Cryns 11.01.2016 IMI webinar Big Data for Better Outcomes (BD4BO) Initiative within IMI2 Goal Support
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease Impact of Big Data Analytics on Healthcare 4-5 October 2017, Luxembourg Dr
Innovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
The Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
Leveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions
Leveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions Author: Richard Bergstrom * Date: 14.11.2016 * Version: 1 Disruption 2 Why this discussion now Definitions.
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative 27.11.2017 15:00 CET Agenda How to use GoToWebinar Catherine Brett,
The European Health Data & Evidence Network
The European Health Data & Evidence Network What is it? Nigel Hughes EFPIA Coordinator Scientific Director, JCI Patient Data for Research, Janssen 18 th May 2018 1 All too often real world research is
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
Public private partnerships to encourage patient access
Public private partnerships to encourage patient access 5 th SFE SFUS Conference Challenges for efficient health care in Central and Eastern Europe Belgrade, 10 th October 2015 How does IMI work? The Innovative
Creation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
Using local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
The International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
Topic: Blockchain Enabled Healthcare
Topic: Blockchain Enabled Healthcare All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by
EU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
IMI WEB-RADR (recognising adverse reactions) project: goals and current activities
IMI WEB-RADR (recognising adverse reactions) project: goals and current activities 4 March 2015 EMA Human Scientific Committees' Working Parties with Patients and Consumers Organisations (PCWP) and Healthcare
EUnetHTA. European network for Health Technology Assessment. European network for Health Technology Assessment JA
EUnetHTA European network for Health Technology Assessment Outline The Making of EUnetHTA EUnetHTA and the HTA Network EUnetHTA Achievements and Tools General Information about HTA 2 The Making of EUnetHTA
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now 11 December 2017 15:00 CET Agenda How to use GoToWebinar
Citation for the original published paper (version of record):
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Patient. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
IMI code of practice for the secondary use of health data. Anne Bahr, PhD, CIPP/E R&D Privacy Officer
IMI code of practice for the secondary use of health data Anne Bahr, PhD, CIPP/E R&D Privacy Officer Presentation Overview The issue The Code of Practice The Code s Article Status and Next Steps Biobanking
Università Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
Webinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
Webinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery 16 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction
Pan European Paediatric Clinical Trials Network From idea to realization
Pan European Paediatric Clinical Trials Network From idea to realization Heidrun Hildebrand, Bayer Ag Mark Turner, University of Liverpool 2 Nordic Pediatric Conference Helsinki, May 21/22, 2018 This project
KPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
Dr. Stefano Vella, Istituto Superiore di Sanitá, Italy
TO-Reach - Transfer of Organisational innovations for Resilient, Effective, equitable, Accessible, sustainable and Comprehensive Health services and systems Dr. Stefano Vella, Istituto Superiore di Sanitá,
The Innovative Medicines Initiative
Joining forces to accelerate biomedical innovation The Innovative Medicines Initiative www.efpia.eu What s in IMI? In IMI the industry and the Commission are partners IMI delivers solutions for patients
THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH
THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH Georges De Moor EuroRec, Ghent University Electronic Health Records for Clinical Research 192 Growing number of Participating Projects
European contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT
The Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
Topic: Blockchain Enabled Healthcare
Topic: Blockchain Enabled Healthcare All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by
Return of Results Aggregate and Individual
Return of Results Aggregate and Individual Jessica Scott, MD, JD Head of R&D Patient Engagement, Takeda David Leventhal Senior Director Clinical Innovation, Pfizer March 18, 2019 Disclaimer The views and
23-26 OCTOBER 2017 INNOVATION IN ACTION EUROPEAN PARLIAMENT STRASBOURG. Meet the EU s research and innovation public-private partnerships
23-26 OCTOBER 2017 INNOVATION IN ACTION EUROPEAN PARLIAMENT STRASBOURG Meet the EU s research and innovation public-private partnerships Meet the EU s research public-private partnerships Bio-based Industries
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
NEXT Annual Report 2017
NEXT Annual Report 2017 June 2018 Final version NEXT Annual Report 2017 Executive Summary The number of early clinical trials carried out in the centers exceeded the number anticipated in the original
EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES. Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium
EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium Electronic Health Records for Clinical Research Re-use of EHR data for optimizing Clinical
Stakeholder Consultation Strategy
Stakeholder Consultation Strategy Strengthening of the EU cooperation on Health Technology Assessment (HTA) 1. Context The present stakeholder consultation aims to provide broad and high quality information
Rare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
Update on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network
Update on the IMI2 Proposal to Build a Sustainable pan- European Paediatric Clinical Trials Network William R Treem, M.D.;* Child Health Innovation and Leadership Department, Johnson and Johnson October
Making the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
Overview: Towards a European open source knowledge management infrastructure. Scott Wagers, MD BioSci Consulting
Overview: Towards a European open source knowledge management infrastructure Scott Wagers, MD BioSci Consulting Innovative Medicines Initiative: Joining Forces in the Healthcare Sector U-BIOPRED Annual
TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES. Establishing the Value of EHR4CR for Pharmaceutical Industry
TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES Establishing the Value of EHR4CR for Pharmaceutical Industry BACKGROUND In the current healthcare environment, bringing a new drug
6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels
www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS
Partnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
CDISC Journal. Current status and future scope of CDISC standards. By Rebecca D. Kush, President and CEO, CDISC. 1. Introduction
CDISC Journal Clinical Data Interchange Standards Consortium oc tober 2012 Current status and future scope of CDISC standards By Rebecca D. Kush, President and CEO, CDISC 1. Introduction In translational
Quality Assurance in nonregulated. pharmaceutical industry. Thomas Steckler
Quality Assurance in nonregulated research of the pharmaceutical industry Thomas Steckler The views expressed in this presentation are solely those of the individual authors, and do not necessarily reflect
From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013
Clinical Trials: Facts and Trends Dr Nik Nikitin Founder/Director, Russlan Clinical What is a clinical trial? A clinical trial is a research study in human volunteers to answer specific health questions
Update on the Drug Safety and
Update on the Drug Safety and Effectiveness Network The Canadian Association for Population Therapeutics March 30, 2010 Dr. Robert Peterson Executive Director, Drug Safety and Effectiveness Network Canadian
Scientific Advisory Board. Report of the first meeting
Scientific Advisory Board Report of the first meeting Utrecht, The Netherlands, May 15 and 16, 2017 1 1) Introduction With this document, the Scientific Advisory Board reports on its discussions held in
The Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
Europe, a world leader in Nanotechnologies, Biomaterials and Micro-Nano-Electronics for Healthcare
Europe, a world leader in Nanotechnologies, Biomaterials and Micro-Nano-Electronics for Healthcare Nicolas Gouze, General Secretary of ETP Nanomedicine Trends & paradigmshifts in Healthcare Demographic
For personal use only. Annual General Meeting 13 November 2017
Annual General Meeting 13 November 2017 Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all
The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
INTERNATIONAL PROJECT MANAGEMENT:
INTERNATIONAL PROJECT MANAGEMENT: LEADERSHIP IN COMPLEX ENVIRONMENTS International Project Management: Leadership in Complex Environments Copyright 2010 John Wiley & Sons, Inc. ISBN: 978-0-470-57882-7
Maternal, Neonatal Health and Developmental Research Network SAMID (RD16/0021/0001)
Maternal, Neonatal Health and Developmental Research Network SAMID (RD16/0021/0001) Máximo Vento MD PhD National Coordinator RETICS RED SAMID Division of Neonatology University & Polytechnic Hospital la
Friedrich Asmus IMI webinar
Webinar IMI2 - Call 7 Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention Friedrich Asmus IMI webinar 19.01.2016
Update on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) Feedback from 797 patient groups in Europe PUBLISHED APRIL 2016 The perception [of pharma] has changed in the last years,
Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
Next Generation Molecular Diagnostics in Scotland. Dr Mark Drummond Haematologist, Beatson Cancer Centre
Next Generation Molecular Diagnostics in Scotland Dr Mark Drummond Haematologist, Beatson Cancer Centre Outline Precision Medicine Regulatory and Funding background in Scotland (briefly) The Gap in the
State of play and outlook
Health in Horizon 2020 State of play and outlook European High level meeting Madrid, 2 nd October 2012 Didier Gambier, Head of the Horizontal Aspects Unit, Health Directorate Directorate-General for European
Public private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
EBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
Webinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
Webinar IMI2 - Call 9 Data quality in preclinical research and development. Thomas Steckler IMI webinar
Webinar IMI2 - Call 9 Data quality in preclinical research and development Thomas Steckler 11.04.2016 IMI webinar Need for public-private collaboration Low quality data hamper innovation and progress in
Innovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
Disclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
Public - Private Partnerships in Europe and ENCePP Initiative
Public - Private Partnerships in Europe and ENCePP Initiative Henry Fitt Section Head, Co-ordination & Networking, Pharmacovigilance and Risk Management European Medicines Agency 22nd Annual EuroMeeting
CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016 Dans notre domaine de maladies rares où des efforts ont été faits pour
Precision Medicine Catapult
Precision Medicine Catapult Building on UK excellence - Growing the precision medicine industry April 2015 catapult.org.uk @PMCatapult Precision Medicine Catapult scale, quality, speed National innovation
Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success!
Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success! David J. Gallacher, PhD DDI Co-Lead, Global Head of Safety Pharmacology
The contribution of the Central & Eastern European Genetic Network (CEEGN) towards prevention and treatment of genetic diseases
Working together for a voice in research & health policies and benefiting from genetics, genomics & biotechnology The contribution of the Central & Eastern European Genetic Network (CEEGN) towards prevention
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease 09.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Iwona Jablonska,
Novartis Response to the Commission Consultation. Rare Diseases: Europe s Challenge
Novartis Response to the Commission Consultation Rare Diseases: Europe s Challenge A Introduction As a Swiss company operating globally out of Europe, Novartis employs more than 100,000 people, half of
Exemplary Project. COILED THE NETHERLANDS April 2018
Exemplary Project COILED THE NETHERLANDS April 2018 This document was prepared as part of the EU-funded project: ESIF Support in the area of health: building knowledge and capacities for monitoring and
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL PUBLIC CONSULTATION
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Healthcare systems Health systems and products PUBLIC CONSULTATION Brussels, 31 July 2012 on the modalities of stakeholder consultation in the
HOW CAN AN ADAPTIVE TRAINING PROGRAMME SUPPORT CHANGE IN ORGANISATIONAL STRATEGY? Dr Karine Palin
HOW CAN AN ADAPTIVE TRAINING PROGRAMME SUPPORT CHANGE IN ORGANISATIONAL STRATEGY? Dr Karine Palin Lifelong Learning in the Biomedical Sciences EMBL Heidelberg, Germany - 5-7 Jul 2016 LEGAL NOTICE DISCLAIMER
EFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ)
EFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ) Disclaimer I am an employee of Chiesi Farmaceutici s.p.a (Head of Clinical Safety
Biomarkers and Patient s Access to Personalized Oncology Drugs in Europe
CDDF Cancer Drug Development Forum CDDF MULTI - STAKEHOLDER WORKSHOP Biomarkers and Patient s Access to Personalized Oncology Drugs in Europe Brussels, Belgium 24-25 September 2018 PROGRAMME PROGRAMME
COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT. Accompanying document to the
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 15.5.2007 SEC(2007) 569 COMMISSION STAFF WORKING DOCUMENT Accompanying document to the Proposal for the Council Regulation concerning the setting up the
NMBP calls in Leadership in Enabling and Industrial Technologies Work Programme Information Day LEIT & FET Bratislava, 9 September 2014
NMBP calls in 2015 Leadership in Enabling and Industrial Technologies Work Programme 2014-15 Information Day LEIT & FET Bratislava, 9 September 2014 José-Lorenzo Vallés DG Research and Horizon 2020: Key
Headline Verdana Bold
Headline Verdana Bold Proposal for a study report on Belgium as clinical trial location in Europe Belgium as clinical trial location in Europe Presentation of results for 2016 4 May 2018 Methodology of
IMI: A Public Private Partnership Funder
IMI: A Public Private Partnership Funder 25-26 July 2011, European Medicines Agency Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy The Innovative Medicines Initiative (IMI):
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record
Public-Private Partnerships in FP7 and in Horizon 2020
Public-Private Partnerships in FP7 and in Horizon 2020 Andrea GENTILI Industrial Technologies DG Research and Innovation Brussels, 27 June 2013 Horizon 2020: Key elements Three pillars: societal challenges,
JOINT TECHNOLOGY INITIATIVES
JOINT TECHNOLOGY INITIATIVES in the Seventh Framework Programme Etienne Magnien Prague, 30 October, 2008 JOINT TECHNOLOGY INITIATIVES General principles 1. General principles 2. Specificities 3. Launch
Neurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European